Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Baxter Pharmaceuticals India Pvt Ltd
483
•Baxter Pharmaceuticals India Pvt Ltd•January 27, 2023

Baxter Pharmaceuticals India Pvt Ltd – FDA 483, Jan 27, 2023

Record Details

The FDA inspected Baxter Pharmaceuticals India Pvt Ltd from January 19 to January 27, 2023, issuing a Form 483 that cited numerous deviations from Current Good Manufacturing Practices (cGMP). Significant observations included a widespread failure to thoroughly investigate unexplained discrepancies and batch failures. This encompassed inadequacies in automatic visual inspection processes, where deficient equipment continued in use, and scientifically unsound root cause investigations for Out-of-Specification (OOS) results in product purity and particulate matter. The facility also exhibited poor equipment maintenance, with damaged and unclean components often tagged as 'cleaned.' Cleaning procedures themselves lacked detail and verification, leading to potential contamination risks. Operational and facility design issues were noted, hindering aseptic operations and proper cleaning. Furthermore, the inspection uncovered deficiencies in production and process controls, with visual inspectors failing to adhere to procedures and lacking scientific rationale for acceptance criteria. Critical gaps in preventing microbiological contamination, such as unestablished product hold times and gowning breaches, were observed. Data integrity was compromised by the destruction of original GMP documents and uncontrolled record-keeping practices. Finally, laboratory controls were found inadequate, with an unregistered R&D unit performing analytical method validation without proper oversight or scientifically sound procedures. Baxter Pharmaceuticals India Pvt Ltd must implement comprehensive corrective and preventive actions to address these findings and ensure compliance with regulatory standards.

Company
Baxter Pharmaceuticals India Pvt Ltd
Inspection date
January 27, 2023
Product type
drugs
Office
Office of Biological Products Operations - Division I
People
  • Pratik S. Upadhyay
  • Justin A. Boyd (Research Specialist II)
View Company Profile

ID · 25cb0e8f-58f3-4a60-a7e3-bac9f78f52c8

Other documents for Baxter Pharmaceuticals India Pvt Ltd
  • 483 - 2025-06-27June 27, 2025
  • 483 - 2022-05-17May 17, 2022
  • 483 - 2017-08-04August 4, 2017
  • 483 - 2016-08-26August 26, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Baxter Pharmaceuticals India Pvt Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.